Lipertance

Amlodipine besilate, the active ingredient in Lipertance, is a combination calcium channel blocker, ACE inhibitor, and HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It is indicated for the management of hypertension, hyperlipidemia, and overall cardiovascular risk reduction in adult patients.

GNH USA supplies Lipertance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable delivery timelines and comprehensive documentation for import clearance.

Lipertance combines three agents that act on blood pressure regulation and lipid metabolism, providing therapeutic benefit in several cardiovascular conditions. - Hypertension: lowers systolic and diastolic pressure through calcium‑channel blockade and ACE inhibition. - Hyperlipidemia: reduces LDL‑cholesterol and total cholesterol by inhibiting HMG‑CoA reductase. - Cardiovascular risk reduction: decreases the likelihood of major adverse cardiac events by simultaneously controlling blood pressure and lipid levels.

Lipertance may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache reported. - Peripheral edema: swelling of ankles or feet. - Dizziness: transient light‑headedness. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, or airway. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Rhabdomyolysis: muscle pain with CK elevation, especially with the statin component.

When prescribing Lipertance, clinicians should consider several safety measures to minimize risk. - Monitor blood pressure: check regularly after initiation and dose changes. - Assess renal function: adjust therapy in severe renal impairment. - Check liver enzymes: baseline and periodic monitoring due to statin component. - Evaluate for pregnancy: avoid use unless benefits outweigh risks. - Review concomitant medications: consider potential drug interactions. - Store at room temperature: keep in original container, protect from moisture and light.

Lipertance can interact with other medicines; some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid): - ACE inhibitor with potassium‑sparing diuretics or supplements: risk of hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase atorvastatin exposure, risk of rhabdomyolysis. - Concomitant use of other calcium‑channel blockers: additive hypotensive effect.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect. - Antacids containing aluminium or magnesium: may reduce absorption of perindopril. - Fibrates (e.g., gemfibrozil): increase risk of statin‑related muscle toxicity.